Aevi Genomic Medicine Inc (NASDAQ:GNMX) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totalling 703,900 shares, a growth of 19.4% from the June 30th total of 589,300 shares. Based on an average daily volume of 1,620,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 2.0% of the shares of the stock are sold short.

NASDAQ:GNMX remained flat at $$0.19 during trading hours on Thursday. 63,150 shares of the company’s stock traded hands, compared to its average volume of 3,719,725. Aevi Genomic Medicine has a twelve month low of $0.15 and a twelve month high of $1.40. The stock has a market cap of $11.96 million, a PE ratio of -0.38 and a beta of 0.73. The stock has a 50-day moving average of $0.18.

Aevi Genomic Medicine (NASDAQ:GNMX) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. Equities research analysts predict that Aevi Genomic Medicine will post -0.27 EPS for the current year.

Separately, ValuEngine raised shares of Aevi Genomic Medicine from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

An institutional investor recently raised its position in Aevi Genomic Medicine stock. Vanguard Group Inc. raised its position in shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 82.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,252,050 shares of the biotechnology company’s stock after purchasing an additional 566,497 shares during the quarter. Vanguard Group Inc. owned 1.93% of Aevi Genomic Medicine worth $201,000 as of its most recent SEC filing. 6.45% of the stock is currently owned by hedge funds and other institutional investors.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Recommended Story: What is a Roth IRA?

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.